FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883450279> ?p ?o ?g. }

• W2883450279 endingPage "5203" @default.
• W2883450279 startingPage "5194" @default.
• W2883450279 abstract "The three encephalitic alphaviruses, western, eastern, and Venezuelan equine encephalitis viruses (WEEV, EEEV, and VEEV) are potential biothreat agents due to high infectivity through aerosol exposure, ease of production in large amounts, and relative stability in the environment. Currently, there is no licensed vaccine for human use to these three encephalitic alphaviruses, and efforts to move vaccine candidates forward into clinical trials have not been successful. In this study, the modified vaccinia Ankara-Bavarian Nordic (MVA-BN®) vaccine platform was used to construct and produce three monovalent recombinant MVA-BN-based encephalitic alphavirus vaccines, MVA-BN-W, MVA-BN-E, and MVA-BN-V. Additionally, a MVA-BN-based construct was designed to produce antigens against all three alphaviruses, the trivalent vaccine MVA-BN-WEV. The protective efficacy of these vaccines was evaluated in vivo. Female BALB/c mice were immunized with two doses of each monovalent MVA-BN-based alphavirus vaccine, a mixture of the three monovalent vaccines, MVA-BN-W + E + V, or the trivalent vaccine MVA-BN-WEV at a four-week interval. Two weeks after the booster immunization, the mice were instilled intranasally with 5 × 103 to 1 × 104 plaque forming units of WEEV, EEEV, or VEEV. All mice immunized with monovalent vaccines survived the respective virus challenge without any signs of illness or weight loss, while all the control mice died. The triple mixture of vaccines or the trivalent vaccine also provided 90 to 100% protection to the mice against WEEV and VEEV challenges, and 60% to 90% protection against EEEV challenge. These data suggest that each monovalent MVA-BN-W, MVA-BN-E, and MVA-BN-V is a potential vaccine candidate against respective encephalitic alphavirus and the three monovalent vaccines can be given in a mixture (MVA-BN-W + E + V) or the trivalent vaccine MVA-BN-WEV can serve as a true multivalent vaccine without significantly reducing efficacy against WEEV and VEEV despite slightly reduced efficacy against EEEV challenge." @default.
• W2883450279 created "2018-08-03" @default.
• W2883450279 creator A5005112554 @default.
• W2883450279 creator A5007037072 @default.
• W2883450279 creator A5066801731 @default.
• W2883450279 creator A5086337383 @default.
• W2883450279 creator A5088122419 @default.
• W2883450279 creator A5091003340 @default.
• W2883450279 date "2018-08-01" @default.
• W2883450279 modified "2023-10-18" @default.
• W2883450279 title "Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses" @default.
• W2883450279 cites W114131869 @default.
• W2883450279 cites W1517159675 @default.
• W2883450279 cites W1874513932 @default.
• W2883450279 cites W1967096834 @default.
• W2883450279 cites W1967516092 @default.
• W2883450279 cites W1968529896 @default.
• W2883450279 cites W1970249843 @default.
• W2883450279 cites W1970758220 @default.
• W2883450279 cites W1976679107 @default.
• W2883450279 cites W1977676160 @default.
• W2883450279 cites W1980041511 @default.
• W2883450279 cites W1994350527 @default.
• W2883450279 cites W1997907373 @default.
• W2883450279 cites W1997940634 @default.
• W2883450279 cites W2001421749 @default.
• W2883450279 cites W2004053206 @default.
• W2883450279 cites W2006363902 @default.
• W2883450279 cites W2014377573 @default.
• W2883450279 cites W2014799103 @default.
• W2883450279 cites W2022158929 @default.
• W2883450279 cites W2026543626 @default.
• W2883450279 cites W2026634313 @default.
• W2883450279 cites W2038391011 @default.
• W2883450279 cites W2039559600 @default.
• W2883450279 cites W2046795466 @default.
• W2883450279 cites W2070609169 @default.
• W2883450279 cites W2071758752 @default.
• W2883450279 cites W2074548951 @default.
• W2883450279 cites W2075200165 @default.
• W2883450279 cites W2077876756 @default.
• W2883450279 cites W2078100710 @default.
• W2883450279 cites W2078129013 @default.
• W2883450279 cites W2081556178 @default.
• W2883450279 cites W2081740252 @default.
• W2883450279 cites W2092732192 @default.
• W2883450279 cites W2098606123 @default.
• W2883450279 cites W2104192496 @default.
• W2883450279 cites W2108218913 @default.
• W2883450279 cites W2122054262 @default.
• W2883450279 cites W2124124821 @default.
• W2883450279 cites W2129821088 @default.
• W2883450279 cites W2151363875 @default.
• W2883450279 cites W2157032531 @default.
• W2883450279 cites W2731692079 @default.
• W2883450279 cites W2787166873 @default.
• W2883450279 doi "https://doi.org/10.1016/j.vaccine.2018.06.064" @default.
• W2883450279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30037666" @default.
• W2883450279 hasPublicationYear "2018" @default.
• W2883450279 type Work @default.
• W2883450279 sameAs 2883450279 @default.
• W2883450279 citedByCount "18" @default.
• W2883450279 countsByYear W28834502792018 @default.
• W2883450279 countsByYear W28834502792019 @default.
• W2883450279 countsByYear W28834502792020 @default.
• W2883450279 countsByYear W28834502792021 @default.
• W2883450279 countsByYear W28834502792022 @default.
• W2883450279 countsByYear W28834502792023 @default.
• W2883450279 crossrefType "journal-article" @default.
• W2883450279 hasAuthorship W2883450279A5005112554 @default.
• W2883450279 hasAuthorship W2883450279A5007037072 @default.
• W2883450279 hasAuthorship W2883450279A5066801731 @default.
• W2883450279 hasAuthorship W2883450279A5086337383 @default.
• W2883450279 hasAuthorship W2883450279A5088122419 @default.
• W2883450279 hasAuthorship W2883450279A5091003340 @default.
• W2883450279 hasBestOaLocation W28834502791 @default.
• W2883450279 hasConcept C147483822 @default.
• W2883450279 hasConcept C159047783 @default.
• W2883450279 hasConcept C203014093 @default.
• W2883450279 hasConcept C2522874641 @default.
• W2883450279 hasConcept C2777062976 @default.
• W2883450279 hasConcept C2777474056 @default.
• W2883450279 hasConcept C2779755945 @default.
• W2883450279 hasConcept C2780801004 @default.
• W2883450279 hasConcept C86803240 @default.
• W2883450279 hasConceptScore W2883450279C147483822 @default.
• W2883450279 hasConceptScore W2883450279C159047783 @default.
• W2883450279 hasConceptScore W2883450279C203014093 @default.
• W2883450279 hasConceptScore W2883450279C2522874641 @default.
• W2883450279 hasConceptScore W2883450279C2777062976 @default.
• W2883450279 hasConceptScore W2883450279C2777474056 @default.
• W2883450279 hasConceptScore W2883450279C2779755945 @default.
• W2883450279 hasConceptScore W2883450279C2780801004 @default.
• W2883450279 hasConceptScore W2883450279C86803240 @default.
• W2883450279 hasIssue "34" @default.
• W2883450279 hasLocation W28834502791 @default.
• W2883450279 hasLocation W28834502792 @default.
• W2883450279 hasOpenAccess W2883450279 @default.

• next